27/05/2026
🙏🏼🙏🏼🙏🏼
Cancer of the bile duct, called cholangiocarcinoma, is a rare, aggressive type of tumor in the liver that has a notoriously poor prognosis. But a newly approved drug will give patients another option to treat cancer that is inoperable, has spread, and is caused by a particular genetic mutation.
The FDA has recently approved zenocutuzumab (Bizengri®) for adults with advanced, unresectable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion. The approval was based results from a clinical trial led by MSK early drug development specialist Dr. Alison Schram.
“Patients with bile duct cancer caused by an NRG1 fusion have very limited treatment options,” Dr. Schram explains. “Zenocutuzumab can make a meaningful difference for these patients, shrinking their tumors with remarkably few side effects — preserving quality of life.”
Learn more about this treatment: https://bit.ly/3Q3VljC
